查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847915

按藥物類別、劑型、通路和最終用戶分類的藥物性失眠治療市場—2025-2032年全球預測

Insomnia Pharmacological Treatment Market by Drug Class, Dosage Form, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，失眠藥物治療市場將成長至 123.7 億美元，複合年成長率為 7.34%。

主要市場統計數據
基準年 2024 70.1億美元
預計年份：2025年 75.2億美元
預測年份：2032年 123.7億美元
複合年成長率 (%) 7.34%

一個全面的失眠藥物治療策略框架，旨在平衡臨床療效、安全性權衡、患者異質性以及不斷變化的治療優先事項。

失眠症仍然是一個複雜的臨床挑戰，涉及神經病學、精神病學、基層醫療和公共衛生等多個領域。藥物治療仍然是許多患者的核心治療手段，尤其是在單純行為介入無法提供充分緩解的情況下。因此，臨床醫生在選擇治療方案時需要權衡療效、安全性、成癮風險和日間功能，而支付者和管理人員則需要考慮處方箋分配和長期依從性。因此，治療方法通常包含多種藥物類別，以針對不同的病理學標靶並滿足患者的偏好。

近年來，鎮靜催眠藥的使用逐漸從傳統的老藥轉向耐受性較好、作用機轉較佳的藥物。這種轉變反映了監管機構對某些苯二氮平類藥物長期使用的審查力度加大，以及人們對Orexin受體拮抗劑和褪黑素受體促效劑興趣的日益成長。同時，由於鎮靜抗憂鬱症在治療合併情緒障礙和失眠方面具有雙重潛力，因此它們被廣泛用於仿單標示外。

臨床實踐越來越重視根據睡眠結構、合併症和患者生活方式量身定做的個人化治療方案。因此，製藥公司和醫療保健系統目前正致力於研發差異化製劑、改進包裝以提高患者依從性，並進行真實世界療效研究。簡而言之，失眠的藥物治療正進入一個新階段，治療方案的選擇不僅要關注改善夜間睡眠質量，還要兼顧安全性和日常功能。

再形成失眠藥物的關鍵變化融合了分子創新、注重實際應用的監管以及數位化醫療模式。

由於科學進步、法規演變和醫療服務模式轉變，失眠治療領域正在經歷變革性變化。首先，分子生物學創新使人們更加關注除γ-氨基丁酸（GABA）調節以外的其他機制，其中Orexin受體拮抗劑作為一種直接作用於覺醒迴路的有效替代方案而脫穎而出。同時，褪黑素受體促效劑的改進和製劑工程的進步，透過緩釋技術調節了失眠的發生和維持。

同時，商業性動態正迫使製造商重新評估其生命週期策略。專利到期和學名藥上市加劇了競爭，推動了對高附加價值製劑、聯合治療以及針對特定患者群體的擴展適應症的投資。與藥物創新相輔相成的是，數位療法和遠端監測工具已成為日常輔助手段，使臨床醫生能夠追蹤睡眠模式並更快地調整藥物治療。

法律規範也在發生變化，更加強調上市後安全性監測和真實世界證據，以指導標籤標註和風險緩解。這種監管力度的加強正在加速觀察性資料流和可操作性臨床試驗的應用，以了解長期療效。總而言之，這些轉變創造了一個更細緻入微、以證據為導向的環境，在這個環境中，產品差異化不僅取決於睡眠指標，還取決於患者功能、耐受性和依從性的顯著改善。

2025年近期貿易政策的變化如何改變了失眠治療供應鏈網路的供應鏈策略、採購動態和價格壓力

2025年關稅及貿易調整措施為失眠藥物的生產和分銷供應鏈帶來了重大曲折點。依賴國際採購的活性藥物原料藥和輔料的製造商立即面臨成本壓力，促使他們重新評估供應商佈局和合約條款。為此，許多公司加快了供應商多元化步伐，提高了安全庫存水平，並尋求近岸生產方案，以降低跨境關稅波動帶來的風險。

這些變化也影響了醫院、藥局和專科診所的籌資策略，促使它們加強庫存管理，並重新重視供應商合格。支付方和合約機構展開了更深入的談判，以抵消潛在的價格影響；藥品福利管理機構重新評估了處方箋目錄，以確保患者的用藥負擔能力。同時，經銷商也調整了物流計劃，以減少因新關稅分類而導致的運輸延誤和合規成本。

從策略角度來看，關稅促使企業重新投資於供應鏈韌性和成本服務模式。企業優先考慮與地域分散的供應商簽訂長期契約，並投資於流程改進以抵消利潤率下降的影響。因此，相關人員採取了一種更為全面的製造經濟觀點，將監管合規、貿易政策風險以及確保藥品送達患者的實際運作納入考量。

深入的分析揭示了治療層級、劑型影響、分銷管道的作用以及最終用戶護理路徑要求等方面的細微差別。

對細分市場的深入理解對於制定滿足臨床醫生期望和患者需求的產品策略至關重要。經典的苯二氮平類藥物，如艾司唑侖、替馬西泮和三唑侖，因其快速起效、強效的催眠作用，仍被需要的患者廣泛使用，但其成癮性和認知方面的副作用需要謹慎管理。褪黑素受體激動劑，如Agomelatine、褪黑素和雷美替胺，因其能夠調節晝夜節律且耐受性良好，尤其適用於晝夜節律紊亂的患者，而備受臨床醫生的青睞。非苯二氮平類促效劑，如Eszopiclone、Zaleplon和Zolpidem，因其在誘導和維持睡眠方面的有效性而仍然十分重要，其中Zolpidem有緩釋性和即時釋兩種劑型，可實現個體化的給藥方案。Orexin受體拮抗劑，例如倫博雷生和蘇沃雷生，其作用機制正轉向抑制覺醒，這反映在專科醫師的處方模式中。當合併情緒或焦慮障礙使睡眠管理複雜化時，鎮靜性抗憂鬱症，例如多塞平和曲唑酮，仍被用作治療手段。

劑型細分會影響患者的用藥依從性和臨床效用。膠囊，無論是硬膠囊或軟膠囊，都便於服用，且因其生物有效性而常被選用。片劑分為控制釋放片和即時釋片，使臨床醫師能夠針對特定睡眠階段給藥，並平衡起效時間和持續時間。劑型與藥物動力學之間的相互作用仍然是選擇治療方案的關鍵因素。

分銷管道細分決定了產品如何觸及患者以及哪些價值提案最為重要。公立和私立醫院藥房優先考慮處方箋穩定性和住院安全，而線上藥房（無論是大眾市場藥房還是專科線上藥房）則強調便利性、持續性護理和處方箋處理效率。零售藥房分為連鎖藥房和獨立藥房，它們在便利性和個人化諮詢之間尋求平衡，從而影響患者的用藥依從性和品牌忠誠度。

終端用戶細分能夠捕捉不同的護理管道和服務需求。居家照護機構，包括輔助生活設施和私人居家護理，需要簡化的用藥方案、清晰的看護者指導以及能夠減少用藥錯誤的包裝。綜合醫院和精神病院都需要能夠與急性護理方案相整合並最大限度減少藥物交互作用的藥物。專科診所，例如門診中心和睡眠障礙診所，則專注於精準治療和監測，以最佳化夜間睡眠結構和日間功能。了解這些相互依存的細分市場，有助於制定有針對性的產品設計、管道策略和臨床證據項目，從而將治療方案與實際應用情境相匹配。

以主要全球市場為例，對採用模式、法規細微差別、生產佈局和分銷動態進行比較區域分析

區域動態顯著影響失眠治療藥物的研發、核准、分銷和應用。在美洲，製劑研發者的偏好和支付機制通常傾向於快速獲得創新藥物，而成本控制措施和複方談判則影響長期用藥模式。在北美臨床實踐中，針對日間功能的新型治療方法的應用正在增加，而遠端醫療的整合也為專科醫生提供了更多服務社區的機會。

在歐洲、中東和非洲，監管差異和醫療保健資金籌措模式的多樣性造成了不同地區的採用率差異。在一些歐洲市場，嚴格的療效比較評估和衛生技術評估被納入報銷決策，這要求製造商提供證據並符合當地的價值框架。同時，在一些中東和非洲市場，私營部門的採用速度正在加快，私立醫院和專科診所正在推動差異化治療方法的早期應用。

亞太地區既是製造業中心，也是充滿活力的市場，各國臨床實務各有不同。學名藥產量龐大，而睡眠醫學專家高度集中的都市區對新型藥物的需求旺盛。數位醫療在亞太部分地區迅速普及，推動了將藥物治療與遠距監測和行為介入相結合的混合醫療模式的發展。因此，每個地區的具體情況都需要量身定做的監管溝通計畫、供應鏈規劃和商業策略，這些都需要考慮到當地臨床醫生的偏好、支付方結構和分銷管道的優勢。

策略性企業行動指南概述了投資組合多元化、供應鏈韌性、生命週期管理和數位化夥伴關係，以增強失眠治療效果。

主要企業正採用多管齊下的策略來保持競爭力並提供臨床價值。產品系列多元化是重中之重，各公司在保留現有藥物的同時，也投資於下一代作用機制和製劑改進。許可和策略聯盟能夠加速新型化合物的獲取，並以外部創新補充內部研發能力。

在營運方面，製造商正專注於建立具有韌性的供應鏈，並遵循品質源自設計的原則，以降低貿易和生產風險。與受託製造廠商和原料藥供應商建立策略聯盟，既能確保產能，又能實現靈活的規模化生產。在商業方面，隨著學名藥進入市場，製造商正積極推行生命週期管理策略（緩釋性、複方製劑、擴大適應症等），以實現差異化競爭。

此外，企業正日益整合數位健康夥伴關係，利用依從性工具、睡眠追蹤器、臨床醫師儀表板等來增強藥物治療效果。此類組合不僅有助於提高患者參與度，還能產生真實世界證據，從而在與支付方的討論中凸顯產品價值。併購仍然是獲取在研產品、分銷管道和治療領域專業知識以加速市場進入和擴大商業性覆蓋範圍的戰術性策略。

針對製造商、支付者和醫療保健提供者，提出切實可行的高優先建議，以最佳化失眠治療產品的價值、供應鏈的穩定性以及以患者為中心的治療效果。

產業領導者應優先採取實際行動，將臨床差異化與永續的商業模式結合。首先，應投資於能夠展現功能性結果的臨床項目，例如日間表現和認知安全性，以及夜間指標。這些數據將增強對支付方和製劑生產商的價值提案。同時，應拓展控制釋放和軟膠囊的選擇範圍，並加速製劑創新，以提高老年人和多重用藥族群的用藥依從性。

在供應方面，我們將對關鍵原料藥實施多通路採購策略，並建立緊急生產協議以應對貿易中斷的影響。我們將積極與採購和支付相關人員溝通，制定風險分擔和管理准入協議，在應對成本壓力的同時，確保藥物供應。同時，我們將與數位療法提供者建立夥伴關係，整合藥物和行為介入措施，從而改善長期療效並支持真實世界證據的產生。

在商業性，我們將根據當地市場動態調整通路策略：加強與醫療機構醫院處方集委員會的關係，最佳化線上藥局通路的電履約，並支援獨立零售合作夥伴的定向教育和用藥依從性計畫。最後，我們將與監管機構保持持續的溝通，利用上市後數據和可操作的研究成果，調整不同地區的藥品標籤，並支持新市場准入。

採用穩健的混合方法研究途徑，結合臨床醫師訪談、病患見解、監管審查和資料三角驗證，以產生有效的失眠治療市場觀點。

本分析的調查方法採用嚴謹的混合方法，以確保其可靠性和有效性。主要研究包括對睡眠醫學專家、精神科醫生、藥劑師、醫院製劑人員和行業高管進行結構化訪談和定性討論，以了解臨床實踐模式、採購行為和戰略重點。來自患者和看護者的回饋探討了依從性和耐受性，這些因素會影響實際療效。

二級研究利用同儕審查文獻、監管指導文件、臨床試驗註冊庫和藥品品質標準來檢驗作用機制和安全性數據。競爭情報流程整合了已發表的文件、專利文獻和產品標籤，繪製了產品組合策略和生命週期事件圖。數據三角測量技術協調了不同的輸入訊息，並強調了獨立來源之間的一致性。

分析方法包括對定性輸入進行主題編碼，以及採用比較框架評估產品和通路屬性。限制包括各地區縱向真實世界數據的可用性有限，以及配方指南的異質性。為減少偏差，本研究與多位專家進行了交叉驗證，並記錄了資料來源以確保結果的可重複性。所有關鍵互動均遵循倫理考量和資料保護標準，匿名報告則保護了受訪者的隱私。

簡潔扼要的結論，整合了臨床創新、營運韌性和市場需求，以指南失眠藥物治療的策略行動。

失眠的藥物治療正處於曲折點特定機制的創新、不斷發展的分銷管道以及供應鏈的韌性正在共同塑造未來的治療模式。臨床醫師越來越傾向於選擇不僅能改善夜間睡眠指標，還能維持日間功能和認知功能的治療方法。因此，Orexin受體拮抗劑、純化褪黑素促效劑以及各種差異化製劑正日益受到臨床和商業性的重視。

同時，不斷變化的貿易政策和來自學名藥的競爭壓力迫使企業採取整體策略，整合可靠的證據產生、靈活的供應鏈設計和精準的商業化策略。區域差異和多樣化的分銷管道要求企業制定符合監管預期和支付方動態的區域參與計畫。最終，那些將嚴謹的臨床項目與務實的營運措施相結合的相關人員，將更有能力為患者和醫療保健系統創造永續的價值。

透過優先考慮高品質的結果數據，投資於以患者為中心的配方和支援服務，並加強供應鏈以應對政策和市場波動，醫療保健相關人員可以滿足失眠患者的複雜需求，同時保持商業性可行性和臨床信譽。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 雙重Orexin受體拮抗劑作為慢性失眠第一線治療藥物的出現
  • 低劑量褪黑激素受體促效劑在老年失眠患者的應用日益廣泛
  • 一項新型GABA-A正向變構調節因子改善睡眠維持的臨床研究結果
  • 針對失眠症夜間覺醒的緩釋性的研發
  • 整合藥物基因組學分析以實現失眠治療方案的個人化選擇
  • 擴大非處方鎮靜催眠藥的選擇範圍及其對劑量的影響
  • 臨床實務中，越來越多的失眠藥物治療合併使用數位化依從性監測。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的失眠藥物治療市場

  • 苯二氮平類藥物
    • 艾司唑侖
    • 替馬西泮
    • 三唑侖
  • 褪黑素受體促效劑
    • Agomelatine
    • 褪黑素
    • 拉丁美洲利提翁
  • 非苯二氮平類催眠藥
    • Eszopiclone
    • Zaleplon
    • Zolpidem
      • 加長版
      • 即時發布
  • Orexin受體拮抗劑
    • 倫博雷桑
    • 蘇沃雷桑
  • 鎮靜性抗憂鬱症
    • 多塞平
    • 曲唑酮

9. 按劑型分類的失眠藥物治療市場

  • 膠囊
    • 硬明膠
    • 軟明膠
  • 口服懸浮液
  • 藥片
    • 控釋
    • 即時發布

10. 按分銷管道分類的失眠藥物治療市場

  • 醫院藥房
    • 私人的
    • 公共
  • 網路藥房
    • 市場
    • 專業網路藥房
  • 零售藥房
    • 鏈
    • 獨立

第11章 以最終用戶分類的失眠藥物治療市場

  • 居家照護
    • 輔助生活設施
    • 私人居家醫療
  • 醫院
    • 綜合醫院
    • 精神病院
  • 專科診所
    • 門診部
    • 睡眠障礙診所

12. 各地區藥物治療失眠市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 失眠藥物治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國藥物治療失眠市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Eisai Co., Ltd.
    • Idorsia Pharmaceuticals Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Novartis AG
    • Aa Pharma Inc.
    • Eisai Co., Ltd.
    • Makers Nutrition, LLC
Product Code: MRR-FB6C9E792FEB

The Insomnia Pharmacological Treatment Market is projected to grow by USD 12.37 billion at a CAGR of 7.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.01 billion
Estimated Year [2025] USD 7.52 billion
Forecast Year [2032] USD 12.37 billion
CAGR (%) 7.34%

A comprehensive framing of pharmacological strategies for insomnia that balances clinical efficacy, safety trade-offs, patient heterogeneity, and evolving therapeutic priorities

Insomnia persists as a complex clinical challenge that intersects neurology, psychiatry, primary care, and public health. Pharmacological treatment remains a central pillar for many patients, particularly where behavioral interventions alone fail to deliver sufficient relief. Clinicians therefore balance efficacy, safety, dependency risk, and daytime functioning when selecting therapeutics, while payers and administrators factor in formulary placement and long-term adherence. As a result, the therapeutic landscape comprises multiple drug classes that address diverse pathophysiological targets and patient preferences.

Recent years have seen a migration from older sedative-hypnotics toward agents that offer improved tolerability profiles and targeted mechanisms. This shift reflects growing regulatory scrutiny over long-term use of certain benzodiazepines and a parallel rise in interest in orexin receptor antagonists and melatonin receptor agonists. Meanwhile, sedating antidepressants remain widely used off-label due to their dual therapeutic effects for comorbid mood disorders and insomnia, which underscores the importance of integrated care pathways.

Clinical practice increasingly emphasizes personalized regimens aligned with sleep architecture, comorbidities, and patient lifestyle. Consequently, pharmaceutical manufacturers and health systems now focus on differentiated formulations, adherence-supporting packaging, and real-world outcomes research. In short, pharmacological management of insomnia is entering a phase in which therapeutic selection is as much about aligning safety and daily functioning as it is about improving nocturnal sleep measures.

Key transformative changes reshaping insomnia pharmacotherapy that combine molecular innovation, regulatory real-world emphasis, and digitally enabled care models

The landscape of insomnia treatment is undergoing transformative shifts driven by scientific advances, regulatory evolution, and changing care delivery models. First, molecular innovation has prioritized mechanisms beyond gamma-aminobutyric acid modulation, with orexin receptor antagonists emerging as a notable alternative that addresses wakefulness circuitry directly. Concurrently, refinements in melatonin receptor agonists and formulation engineering have sought to reconcile onset and maintenance insomnia through modified-release technologies.

At the same time, commercial dynamics have compelled manufacturers to rethink lifecycle strategies. Patent expirations and generic entry have heightened competition, stimulating investment in value-added formulations, combination approaches, and label expansions that target specific patient cohorts. Parallel to pharmacologic innovation, digital therapeutics and remote monitoring tools have become routine adjuncts, enabling clinicians to track sleep patterns and adjust pharmacotherapy more responsively.

Regulatory frameworks have also shifted, with agencies emphasizing post-marketing safety surveillance and real-world evidence to inform labeling and risk mitigation. This regulatory focus has accelerated the adoption of observational data streams and pragmatic clinical trials to capture long-term outcomes. Taken together, these shifts have created a more nuanced, evidence-driven environment where product differentiation hinges on demonstrable improvements in patient functioning, tolerability, and adherence rather than sleep metrics alone.

How recent trade policy shifts in 2025 have reshaped supply chain strategies, procurement dynamics, and pricing pressures across insomnia pharmacological supply networks

The imposition of tariffs and trade adjustments in 2025 created a material inflection point for supply chains that support insomnia pharmacological manufacturing and distribution. Manufacturers that rely on internationally sourced active pharmaceutical ingredients and excipients experienced immediate cost pressures, catalyzing re-evaluations of supplier footprints and contractual terms. In response, many organizations accelerated supplier diversification, increased safety stock levels, and pursued near-shore manufacturing options to reduce exposure to cross-border tariff volatility.

These changes had downstream effects on procurement strategies within hospitals, pharmacies, and specialty clinics, prompting tighter inventory management and renewed emphasis on supplier qualification. Payers and contracting entities engaged in more intensive negotiations to offset potential price impacts, while pharmacy benefit managers revisited formulary placements to preserve affordability for patients. In parallel, distributors recalibrated logistics planning to mitigate transit delays and compliance costs associated with new tariff classifications.

Strategically, the tariffs prompted renewed investment in supply chain resilience and cost-to-serve modeling. Companies prioritized long-term agreements with geographically diversified suppliers and invested in process improvements to offset margin compression. Consequently, stakeholders adopted a more holistic view of manufacturing economics that integrates regulatory compliance, trade policy risk, and the operational realities of getting medications to patients reliably.

In-depth segmentation-driven insights revealing therapeutic class nuances, dosage form implications, distribution channel roles, and end user care pathway requirements

A nuanced understanding of market segments is essential to design product strategies that meet clinician expectations and patient needs. Drug class segmentation underscores divergent therapeutic priorities: classic benzodiazepines such as estazolam, temazepam, and triazolam continue to serve patients who need rapid onset and strong hypnotic effects, yet they prompt careful stewardship due to dependency and cognitive side effect profiles. Melatonin receptor agonists, including agomelatine, melatonin, and ramelteon, appeal to clinicians seeking circadian alignment and favorable tolerability, especially for patients with circadian rhythm disturbances. Non-benzodiazepine hypnotics like eszopiclone, zaleplon, and zolpidem remain important for their efficacy in sleep initiation and maintenance, with zolpidem available in both extended-release and immediate-release formats to tailor dosing strategies. Orexin receptor antagonists such as lemborexant and suvorexant represent a mechanistic shift toward wakefulness inhibition, which has resonated in specialist prescribing patterns. Sedating antidepressants, notably doxepin and trazodone, persist in therapeutic arsenals when comorbid mood or anxiety disorders complicate sleep management.

Dosage form segmentation shapes both adherence and clinical utility. Capsules, whether hard gelatin or soft gelatin, offer convenient dosing and are often chosen for bioavailability considerations, whereas oral suspensions provide dosing flexibility for pediatric or geriatric cohorts. Tablets, in controlled-release or immediate-release formats, enable clinicians to target specific sleep phases and balance onset with duration. The interplay between form and pharmacokinetics remains a decisive factor in regimen selection.

Distribution channel segmentation determines how products reach patients and which value propositions matter most. Hospital pharmacies in private and public settings prioritize formulary stability and inpatient safety, while online pharmacies, whether large marketplaces or specialty online providers, emphasize convenience, continuity of care, and prescription fulfillment efficiencies. Retail pharmacies, split between chain and independent operators, balance accessibility with personalized counseling, influencing adherence and brand loyalty.

End user segmentation captures divergent care pathways and service requirements. Homecare settings, including assisted living and private homecare, demand simplified regimens, clear caregiver instructions, and packaging that reduces dosing errors. Hospitals, both general and psychiatric, require medications that integrate with acute care protocols and minimize drug-drug interactions. Specialty clinics, such as outpatient centers and dedicated sleep disorder clinics, focus on precision therapies and monitoring to optimize nocturnal architecture and daytime functioning. Understanding these interdependent segments enables targeted product design, channel strategies, and clinical evidence programs that align therapeutic attributes with real-world use cases.

Comparative regional analysis highlighting adoption patterns, regulatory nuances, manufacturing footprints, and distribution dynamics across major global markets

Regional dynamics materially influence how insomnia therapies are developed, approved, distributed, and adopted. In the Americas, prescriber preferences and payer mechanisms often favor rapid access to innovative agents, while cost containment measures and formulary negotiations shape long-term utilization patterns. North American clinical practice has shown notable uptake of newer mechanisms that emphasize daytime functioning, and integration of telehealth has increased specialist reach into community settings.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse healthcare funding models create a mosaic of adoption rates. In several European markets, rigorous comparative effectiveness assessments and health technology appraisals inform reimbursement decisions, prompting manufacturers to align evidence generation with local value frameworks. Meanwhile, certain Middle Eastern and African markets exhibit accelerated private sector uptake where private hospitals and specialty clinics can drive early utilization of differentiated therapies.

The Asia-Pacific region serves both as a manufacturing hub and a dynamic market with varied clinical practices across countries. High-volume generic production coexists with strong demand for novel mechanisms in urban centers where sleep medicine specialties concentrate. Rapid digital health adoption in parts of Asia-Pacific has facilitated hybrid care models that combine pharmacotherapy with remote monitoring and behavioral interventions. Each regional context therefore requires a tailored regulatory engagement plan, supply chain mapping, and commercial strategy that accounts for local clinician preferences, payer structures, and distribution channel strengths.

Strategic corporate playbook outlining portfolio diversification, supply chain resilience, lifecycle management, and digital partnerships to strengthen insomnia treatment offerings

Leading companies in the insomnia pharmacotherapy space are adopting multi-pronged strategies to sustain competitiveness and deliver clinical value. Product portfolio diversification ranks highly, with firms maintaining legacy agents while investing in next-generation mechanisms and formulation enhancements. Licensing arrangements and strategic collaborations accelerate access to novel compounds and complement internal R&D capabilities with external innovation.

Operationally, manufacturers emphasize resilient supply chains and quality-by-design principles to mitigate trade and manufacturing risks. Strategic alliances with contract manufacturing organizations and API suppliers help secure capacity while enabling agile scale-up. Commercially, companies pursue lifecycle management strategies-such as extended-release formulations, fixed-dose combinations, and indication expansions-to differentiate offerings as generics enter the market.

Moreover, a growing number of firms are integrating digital health partnerships to augment pharmacotherapy with adherence tools, sleep trackers, and clinician dashboards. These combinations not only support patient engagement but also generate real-world evidence to underscore product value in payer discussions. Mergers and acquisitions continue to be a tactical route for acquiring pipeline assets, distribution footprints, and therapeutic expertise that accelerate market access and broaden commercial reach.

Practical and prioritized recommendations for manufacturers, payers, and providers to optimize product value, supply resilience, and patient-centered outcomes in insomnia care

Industry leaders should prioritize concrete actions that align clinical differentiation with sustainable commercial models. First, invest in clinical programs that demonstrate functional outcomes such as daytime performance and cognitive safety in addition to nocturnal measures; these data will strengthen value propositions with payers and prescribers. Simultaneously, accelerate formulation innovation by expanding controlled-release and soft gelatin capsule options to improve adherence across geriatric and polypharmacy populations.

On the supply side, implement multi-sourcing strategies for key APIs and establish contingency manufacturing agreements to buffer trade-related disruptions. Engage proactively with procurement and payer stakeholders to design risk-sharing and managed-entry agreements that preserve access while addressing cost pressures. In parallel, forge partnerships with digital therapeutics providers to bundle pharmacologic and behavioral interventions, thereby enhancing long-term outcomes and supporting real-world evidence generation.

Commercially, tailor channel strategies to local market dynamics: strengthen relationships with hospital formulary committees in institutional settings, optimize e-commerce fulfillment for online pharmacy channels, and support independent retail partners with targeted education and adherence programs. Finally, maintain an iterative regulatory engagement plan that leverages post-marketing data and pragmatic studies to adapt labeling and support market access across diverse geographies.

Robust mixed-methods research approach combining clinician interviews, patient insights, regulatory review, and data triangulation to produce validated insomnia drug market perspectives

The research methodology underpinning this analysis combined a rigorous mixed-methods approach to ensure credibility and relevance. Primary research included structured interviews and qualitative discussions with sleep medicine specialists, psychiatrists, pharmacists, hospital formulary decision-makers, and industry executives to capture clinical practice patterns, procurement behaviors, and strategic priorities. Patient and caregiver feedback informed adherence and tolerability considerations that influence real-world effectiveness.

Secondary research leveraged peer-reviewed literature, regulatory guidance documents, clinical trial registries, and pharmaceutical quality standards to validate mechanistic claims and safety profiles. Competitive intelligence processes synthesized public filings, patent literature, and product labeling to map portfolio strategies and lifecycle events. Data triangulation techniques reconciled divergent inputs and emphasized convergence across independent sources.

Analytical methods incorporated thematic coding for qualitative inputs and comparative frameworks to assess product and channel attributes. Limitations included variable availability of longitudinal real-world data across regions and heterogeneity in prescribing guidelines. To mitigate bias, the research applied cross-validation with multiple expert respondents and documented source provenance for reproducibility. Ethical considerations and data protection standards guided all primary interactions, and anonymized reporting protected respondent confidentiality.

Concise conclusion synthesizing clinical innovation, operational resilience, and market imperatives to guide strategic action in insomnia pharmacological care

The pharmacological management of insomnia stands at an inflection point where mechanism-specific innovation, distribution evolution, and supply chain resilience converge to shape future care paradigms. Clinicians increasingly favor therapeutics that not only improve nocturnal sleep metrics but also preserve daytime functioning and cognitive safety. Consequently, orexin receptor antagonists, refined melatonin agonists, and differentiated formulations have assumed greater clinical and commercial importance.

At the same time, trade policy shifts and competitive generic pressures compel organizations to adopt holistic strategies that integrate robust evidence generation, agile supply chain design, and targeted commercialization tactics. Regional heterogeneity and diverse distribution channels necessitate localized engagement plans that respect regulatory expectations and payer dynamics. Ultimately, stakeholders that align rigorous clinical programs with pragmatic operational measures will be best positioned to deliver sustainable value to patients and healthcare systems.

Moving from insight to impact requires deliberate execution: prioritize high-quality outcomes data, invest in patient-centric formulation and support services, and fortify supply chains against policy and market volatility. Doing so will enable healthcare stakeholders to meet the complex needs of patients living with insomnia while maintaining commercial viability and clinical credibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of dual orexin receptor antagonists as first line therapy for chronic insomnia
  • 5.2. Increasing adoption of low-dose melatonin receptor agonists for elderly insomnia patients
  • 5.3. Clinical trial results for novel GABA-A positive allosteric modulators improving sleep maintenance
  • 5.4. Development of extended release formulations targeting middle of the night awakening in insomnia
  • 5.5. Integration of pharmacogenomic profiling to personalize insomnia medication selection
  • 5.6. Expansion of over-the-counter sedative-hypnotic options and its impact on prescription volumes
  • 5.7. Rising use of digital adherence monitoring combined with insomnia pharmacotherapy in clinical practice

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Insomnia Pharmacological Treatment Market, by Drug Class

  • 8.1. Benzodiazepines
    • 8.1.1. Estazolam
    • 8.1.2. Temazepam
    • 8.1.3. Triazolam
  • 8.2. Melatonin Receptor Agonists
    • 8.2.1. Agomelatine
    • 8.2.2. Melatonin
    • 8.2.3. Ramelteon
  • 8.3. Non Benzodiazepine Hypnotics
    • 8.3.1. Eszopiclone
    • 8.3.2. Zaleplon
    • 8.3.3. Zolpidem
      • 8.3.3.1. Extended Release
      • 8.3.3.2. Immediate Release
  • 8.4. Orexin Receptor Antagonists
    • 8.4.1. Lemborexant
    • 8.4.2. Suvorexant
  • 8.5. Sedating Antidepressants
    • 8.5.1. Doxepin
    • 8.5.2. Trazodone

9. Insomnia Pharmacological Treatment Market, by Dosage Form

  • 9.1. Capsules
    • 9.1.1. Hard Gelatin
    • 9.1.2. Soft Gelatin
  • 9.2. Oral Suspension
  • 9.3. Tablets
    • 9.3.1. Controlled Release
    • 9.3.2. Immediate Release

10. Insomnia Pharmacological Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
    • 10.1.1. Private
    • 10.1.2. Public
  • 10.2. Online Pharmacy
    • 10.2.1. Marketplaces
    • 10.2.2. Specialty Online Pharmacies
  • 10.3. Retail Pharmacy
    • 10.3.1. Chain
    • 10.3.2. Independent

11. Insomnia Pharmacological Treatment Market, by End User

  • 11.1. Homecare Settings
    • 11.1.1. Assisted Living
    • 11.1.2. Private Homecare
  • 11.2. Hospitals
    • 11.2.1. General Hospitals
    • 11.2.2. Psychiatric Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Outpatient Clinics
    • 11.3.2. Sleep Disorder Clinics

12. Insomnia Pharmacological Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Insomnia Pharmacological Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Insomnia Pharmacological Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Merck & Co., Inc.
    • 15.3.2. Eisai Co., Ltd.
    • 15.3.3. Idorsia Pharmaceuticals Ltd.
    • 15.3.4. Pfizer Inc.
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
    • 15.3.6. Viatris Inc.
    • 15.3.7. Novartis AG
    • 15.3.8. Aa Pharma Inc.
    • 15.3.9. Eisai Co., Ltd.
    • 15.3.10. Makers Nutrition, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL INSOMN